UCP1 and prostate cancer: Being a single center pilot study, our result demonstrates for the first time that there is a significantly higher PPAT water-to-oil ratio (RWO) compared with the low-risk group (mean 52.12 versus 30.48; 95% CI: 16.32–26.94; p < 0.0001), compatible with the immunofluorescence staining and signal intensities of UCP-1 in immunohistochemistry showing the presence of BAT within PPAT collected in localized patients with prostate cancer.